These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33773271)

  • 41. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.
    van Ballegoij WJC; van de Stadt SIW; Huffnagel IC; Kemp S; Willemse EAJ; Teunissen CE; Engelen M
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2127-2136. PubMed ID: 33047897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
    Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
    J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction.
    Vågberg M; Norgren N; Dring A; Lindqvist T; Birgander R; Zetterberg H; Svenningsson A
    PLoS One; 2015; 10(8):e0135886. PubMed ID: 26317831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
    Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
    Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Temporal response profiles of serum ubiquitin C-terminal hydrolase-L1 and the 145-kDa alpha II-spectrin breakdown product after severe traumatic brain injury in children.
    Metzger RR; Sheng X; Niedzwecki CM; Bennett KS; Morita DC; Zielinski B; Schober ME
    J Neurosurg Pediatr; 2018 Oct; 22(4):369-374. PubMed ID: 29957142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid brain injury biomarkers in children: a multicenter study.
    Shahim P; Darin N; Andreasson U; Blennow K; Jennions E; Lundgren J; Månsson JE; Naess K; Törnhage CJ; Zetterberg H; Mattsson N
    Pediatr Neurol; 2013 Jul; 49(1):31-39.e2. PubMed ID: 23827424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
    Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A
    Front Neurol; 2019; 10():280. PubMed ID: 30972011
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute Temporal Profiles of Serum Levels of UCH-L1 and GFAP and Relationships to Neuronal and Astroglial Pathology following Traumatic Brain Injury in Rats.
    Huang XJ; Glushakova O; Mondello S; Van K; Hayes RL; Lyeth BG
    J Neurotrauma; 2015 Aug; 32(16):1179-89. PubMed ID: 25763798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
    Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
    Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined GFAP, NFL, Tau, and UCH-L1 panel increases prediction of outcomes in neonatal encephalopathy.
    Yang Z; Xu H; Sura L; Arja RD; Patterson RL; Rossignol C; Albayram M; Rajderkar D; Ghosh S; Wang K; Weiss MD
    Pediatr Res; 2023 Apr; 93(5):1199-1207. PubMed ID: 35273370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
    Cross AH; Gelfand JM; Thebault S; Bennett JL; von Büdingen HC; Cameron B; Carruthers R; Edwards K; Fallis R; Gerstein R; Giacomini PS; Greenberg B; Hafler DA; Ionete C; Kaunzner UW; Kodama L; Lock C; Longbrake EE; Musch B; Pardo G; Piehl F; Weber MS; Yuen S; Ziemssen T; Bose G; Freedman MS; Anania VG; Ramesh A; Winger RC; Jia X; Herman A; Harp C; Bar-Or A
    JAMA Neurol; 2024 Mar; 81(4):373-83. PubMed ID: 38466277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.
    Madeddu R; Farace C; Tolu P; Solinas G; Asara Y; Sotgiu MA; Delogu LG; Prados JC; Sotgiu S; Montella A
    Neurol Sci; 2013 Feb; 34(2):181-6. PubMed ID: 22362332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration.
    Pawlitzki M; Schreiber S; Bittner D; Kreipe J; Leypoldt F; Rupprecht K; Carare RO; Meuth SG; Vielhaber S; Körtvélyessy P
    Front Neurol; 2018; 9():1037. PubMed ID: 30631300
    [No Abstract]   [Full Text] [Related]  

  • 57. Idebenone does not inhibit disability progression in primary progressive MS.
    Kosa P; Wu T; Phillips J; Leinonen M; Masvekar R; Komori M; Wichman A; Sandford M; Bielekova B
    Mult Scler Relat Disord; 2020 Oct; 45():102434. PubMed ID: 32784117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
    Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
    J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.